The United Bio-Technology (Hengqin) Co., Ltd., established in 2021 and is located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Zhuhai, serves as the biopharmaceutical R&D headquarters of United Laboratories. The company has formed a professional R&D team led by senior engineers and PhD researchers with expertise in pharmaceutical sciences. The team focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. Since its establishment, the company has been committed to developing 15 projects such as insulin degludec and liraglutide injection, semaglutide, triple agonists, Dupilumab monoclonal antibodies, and dual-target lipid-lowering drugs. The triple agonist developed by the company is the first in China and second in the world as the long-acting GLP-1/GIP/GCG triple agonists prepared by chemical synthesis of polypeptides.